Preview

Российский кардиологический журнал

Расширенный поиск

ФИБРИЛЛЯЦИЯ ПРЕДСЕРДИЙ И СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ: ПОДХОДЫ К АНТИТРОМБОТИЧЕСКОЙ ТЕРАПИИ

https://doi.org/10.15829/1560-4071-2017-7-132-138

Полный текст:

Аннотация

Представлены современные эпидемиологические данные о распространенности, инцидентности фибрилляцией предсердий (ФП) и сопутствующей сердечной недостаточности (СН). Изложены основные доказательства увеличения риска тромбоэмболических осложнений у данной категории пациентов, представлены данные эффективности и безопасности прямых пероральных антикоагулянтов у пациентов с ФП и наличием СН, что может способствовать принятию решений в отношении оптимальной антикоагулянтной терапии у данной больных.

Об авторах

Б. А. Татарский
ФГБУ Северо-Западный федеральный медицинский исследовательский центр им.В.А.Алмазова
Россия
Татарский Борис   Алексеевич  — доктор медицинских наук, профессор, руководитель НИЛ нарушений ритма сердца


С. В. Попов
ФГБУ Томский национальный исследовательский медицинский центр Российской академии наук, Научно-исследовательский институт кардиологии
Россия
Доктор медицинских наук, профессор, академик РАН, зам. директора Томского НИМЦ по научной и лечебной работе


Н. В. Казеннова
ФГБУ Северо-Западный федеральный медицинский исследовательский центр им.В.А.Алмазова
Россия
Научный сотрудник НИЛ клинической аритмологии


Список литературы

1. Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014; 63: 1123-33.

2. Maggioni AP, Dahlstrom U, Filippatos G, et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2013; 15: 808-17.

3. Rewiuk K, Wizner B, Fedyk-Lukasik M, et al. Epidemiology and management of coexisting heart failure and atrial fibrillation in an outpatient setting. Pol Arch Med Wewn 2011; 121: 392-9.

4. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-402.

5. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology and rationale for therapy. Am. J. Cardiol. 2003; 91: 2D-8D.

6. Chiang C, Naditch-Brule L, Murin J, et al. Distribution and risk profile of paroxysmal, persistent and permanent atrial fibrillation in routine clinical practice: insight from the real life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 2012; 5: 632-39.

7. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003; 107: 2920-5.

8. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992; 327: 685-91.

9. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N. Engl. J. Med. 1987; 316: 1429-1435.

10. Miyasaka Y, Barnes ME, Gersh BJ, et al. Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades. Eur. Heart J. 2006; 27: 936-41.

11. Pederson O, Bagger H, Kober L, Torp-Pederson C; for the TRACE Study Group. Impact of congestive heart failure and left ventricular systolic function on the prognostic significance of atrial fibrillation and atrial flutter following myocardial infarction. Int J Cardiol. 2005; 100: 65-71.

12. Olsson L, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction. J Am Coll Cardiol. 2006; 47: 1997-2004.

13. Liang-Han L. Comorbidity of atrial fibrillation and heart failure. Nature Reviews Cardiology 2016;13:131-47.

14. Lalani G, Schricker A, Gibson M, et al. Atrial conduction slows immediately before the onset of human atrial fibrillation: a bi-atrial contact mapping study of transitions to atrial fibrillation. J Am Coll Cardiol 2012; 59: 595-606.

15. Healey J, Israel C, Connolly S, et al. Relevance of electrical remodeling in human atrial fibrillation: results of the asymptomatic atrial fibrillation and stroke evaluation in pacemaker patients and the atrial fibrillation reduction atrial pacing trial mechanisms of atrial fibrillation study. Circ Arrhythm Electrophysiol 2012; 5: 626-31.

16. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacinginduced congestive heart failure. Circulation 2001; 104: 2608-14.

17. Narayan S, Franz M, Clopton P, et al. Repolarization alternans reveals vulnerability to human atrial fibrillation. Circulation 2011; 123: 2922-30.

18. Diagnosis and treatment of atrial fibrillation. Recommendations RSC, RSSA AND ACS, 2012. Russian (Национальные рекомендации по диагностике и лечению фибрилляции предсердий (2012) под эгидой обществ РКО, ВНОА и АССХ http://www.scardio.ru/rekomendacii/rekomendacii_rko/nacionalnye_rekomendacii_po_diagnostike_i_lecheniyu_fibrillyacii_predserdiy_2012).

19. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2016; 18: 12-36.

20. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS European Heart Journal doi:10.1093/eurheartj/ehw210.

21. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure European Heart Journal. 2016. doi:10.1093/eurheartj/ehw128.

22. Vemmos K, Ntaios G, Savvari P, et al. Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study. Eur J Heart Fail 2012; 14: 211-8.

23. Magnani G, Giugliano R, Ruff C, et al. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: Insights from Engage-AFTIMI 48. Circulation. 2014; 130: Abstract 12680.

24. Melgaard L, Gorst-Rasmussen A, Lane Deirdre, et al. Assessment of the CHA2 DS2 -VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation JAMA. 2015; 314 (10): 1030-8.

25. Hijazi Z, Oldgren J, Anderssonc U, et al. Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy. Circulation. 2012; 125: 1605-16.

26. Hijazi Z on behalf of the ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score forpredicting stroke in atrial fibrillation. European Heart Journal doi: 10.1093/eurheartj/ehw054.

27. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138(5): 1093-100.

28. Hijazi Z on behalf of the ARISTOTLE and RE-LY Investigators. The novel biomarker based ABC (age, biomarkers, clinical history) bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016, 327(10035): 2302-11.

29. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146(12): 857-67.

30. Agarwal M, Apostolakis S, Lane DA, Lip GY. The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients: a systematic review. Clin Ther 2014; 36: 1135-44.

31. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis — Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;110:1087-107.

32. Fauchier L, Angoulvant D, Lip GY. The SAMe-TT2R2 score and quality of anticoagulationin atrial fibrillation: a simple aid to decision-making on who is suitable (or not) for vitamin K antagonists. Europace 2015; 17: 671-3.

33. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.

34. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.

35. Granger CB, Alexander JH, McMurray JJ, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. NEngl J Med 2011;365:981-92.

36. Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104.

37. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-62.

38. Chan N, Paikin J, Hirsh J, et al. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions Thromb Haemost 2014; 111: 798-807.

39. Ferreira J, Ezekowitz MD, Connolly SJ, et al. Investigators RE-LY. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Eur J Heart Fail 2013;15:1053-61.

40. van Diepen S, Hellkamp AS, Patel MR, et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail 2013; 6: 740-7.

41. McMurray JJ, Ezekowitz JA, Lewis BS, et al. ARISTOTLE Committees and Investigators. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail 2013; 6: 451-60.

42. Xiong Q, Lau YCh, Senoo K, et al. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. European Journal of Heart Failure (2015) 17, 1192-200.

43. Savarese G, Giugliano RP, Rosano GMC, et al. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure. A Meta-Analysis. J Am Coll Cardiol HF 2016 http://d x.doi.org/10.1016/j.jchf.2016.07.012

44. Nielsen PB, Lane DA, Rasmussen LH, et al. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol 2015;104:418-29.


Для цитирования:


Татарский Б.А., Попов С.В., Казеннова Н.В. ФИБРИЛЛЯЦИЯ ПРЕДСЕРДИЙ И СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ: ПОДХОДЫ К АНТИТРОМБОТИЧЕСКОЙ ТЕРАПИИ. Российский кардиологический журнал. 2017;(7):132-138. https://doi.org/10.15829/1560-4071-2017-7-132-138

For citation:


Tatarsky B.A., Popov S.V., Kazennova N.V. ATRIAL FIBRILLATION AND HEART FAILURE: APPROACHES TO ANTITHROMBOTIC THERAPY. Russian Journal of Cardiology. 2017;(7):132-138. (In Russ.) https://doi.org/10.15829/1560-4071-2017-7-132-138

Просмотров: 234


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)